Optiscan has been featured in Stockhead, highlighting the role Australian medtech companies are playing in advancing medical imaging and the potential for new technologies to provide clinicians with information beyond what can be seen with the human eye.

The article focuses on Optiscan’s approach to bringing microscopic imaging closer to the point of clinical decision-making, highlighting InVue’s potential to provide surgeons with real-time, cellular-level tissue visualisation during procedures and InForm’s ability to generate digital microscopic images directly from fresh or preserved tissue without conventional slide preparation. It also notes the company’s recent regulatory progress, with FDA 510(k) submissions lodged for InForm on 1 October and InVue on 5 October, moving both platforms into formal US regulatory review.

CEO and Managing Director Dr. Camile Farah said: “From breast and head and neck cancer to other solid tumour procedures, the opportunity is to bring cellular-level information directly into the operating theatre where life-changing decisions need to be made.”

He also said of InForm: “The device is not just digitising an existing pathology process. It has real potential to change where and when microscopic information becomes available for clinical use.”

Read the full article here.